Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Everolimus

FDA-approved product (tablet, oral), marketed as Afinitor, Afinitor Disperz, Everolimus and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Everolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Anaplastic astrocytoma
  • Angiomyolipoma
  • Astrocytoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Clear cell renal carcinoma
  • Hamartoma
  • Kidney Angiomyolipoma
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Pancreatic neuroendocrine tumor
  • and 5 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Everolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Everolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

    NCT07566091 · start 2026-06-15

    Registered record
    Registry ID
    NCT07566091
    Conditions
    Coronary Artery Disease
    Interventions
    Sirolimus-Ascorbic Acid Eluting Stent; Everolimus-Eluting Stent
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-06-15
    Completion
    2028-06-15
    Enrolment
    2,034

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionSirolimus-Ascorbic Acid Eluting Stent; Everolimus-Eluting Stent
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

    NCT07463664 · start 2025-04-28

    Registered record
    Registry ID
    NCT07463664
    Conditions
    Chronic Total Occlusions of Coronary Arteries; Chronic Total Occlusion (CTO); Coronary Artery Disease (CAD)
    Interventions
    DES Implantation; DCB Angioplasty
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-28
    Completion
    2026-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Total Occlusions of Coronary Arteries; Chronic Total Occlusion (CTO); Coronary Artery Disease (CAD)
    InterventionDES Implantation; DCB Angioplasty
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

    NCT06680921 · start 2024-11-14

    Registered record
    Registry ID
    NCT06680921
    Conditions
    Locally Advanced or Metastatic Breast Cancer
    Interventions
    SIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-14
    Completion
    2028-08-31
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced or Metastatic Breast Cancer
    InterventionSIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    PhasePhase 3
    Registry statusActive not recruiting

  • Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

    NCT05918302 · start 2023-10-27

    Registered record
    Registry ID
    NCT05918302
    Conditions
    Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
    Interventions
    177Lu-edotreotide; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-10-27
    Completion
    2029-10
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
    Intervention177Lu-edotreotide; Everolimus
    PhasePhase 3
    Registry statusRecruiting

  • Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

    NCT05490095 · start 2021-07-23

    Registered record
    Registry ID
    NCT05490095
    Conditions
    Pharmacokinetics
    Interventions
    SVG101 (T); Afinitor (R)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-23
    Completion
    2022-02-07
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionSVG101 (T); Afinitor (R)
    PhasePhase 1
    Registry statusCompleted

  • Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES

    NCT04135989 · start 2020-01-01

    Registered record
    Registry ID
    NCT04135989
    Conditions
    Coronary Artery Disease; Acute Coronary Syndrome; Chronic Coronary Syndrome; Myocardial Infarction
    Interventions
    Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.; Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.; Personalized DAPT duration; Standard DAPT duration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2024-10-24
    Enrolment
    2,106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Acute Coronary Syndrome; Chronic Coronary Syndrome; Myocardial Infarction
    InterventionPercutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.; Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.; Personalized DAPT duration; Standard DAPT duration
    PhasePhase 4
    Registry statusUnknown

  • Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

    NCT03216967 · start 2018-01-15

    Registered record
    Registry ID
    NCT03216967
    Conditions
    BK Virus Nephropathy After Kidney Transplantation
    Interventions
    everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-15
    Completion
    2024-08-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBK Virus Nephropathy After Kidney Transplantation
    Interventioneverolimus
    PhasePhase 4
    Registry statusCompleted

  • Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association

    NCT03228576 · start 2017-04-14

    Registered record
    Registry ID
    NCT03228576
    Conditions
    Kidney Transplant; Immunosuppression
    Interventions
    Extended release Tacrolimus-Everolimus association
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-04-14
    Completion
    2018-12-18
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant; Immunosuppression
    InterventionExtended release Tacrolimus-Everolimus association
    PhaseNot recorded
    Registry statusTerminated

  • Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation

    NCT02736227 · start 2016-03

    Registered record
    Registry ID
    NCT02736227
    Conditions
    Liver Transplantation
    Interventions
    Tacrolimus Withdrawal and Everolimus Monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-03
    Completion
    2021-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionTacrolimus Withdrawal and Everolimus Monotherapy
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

    NCT02531932 · start 2015-12-16

    Registered record
    Registry ID
    NCT02531932
    Conditions
    Breast Cancer
    Interventions
    Carboplatin; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12-16
    Completion
    2024-10-19
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionCarboplatin; Everolimus
    PhasePhase 2
    Registry statusCompleted

  • Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

    NCT03596970 · start 2015-09

    Registered record
    Registry ID
    NCT03596970
    Conditions
    Liver Transplantation
    Interventions
    TAC withdrawal; Everolimus with reduced TAC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2015-09
    Completion
    2020-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionTAC withdrawal; Everolimus with reduced TAC
    PhasePhase 3
    Registry statusWithdrawn

  • Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

    NCT02029001 · start 2014-03

    Registered record
    Registry ID
    NCT02029001
    Conditions
    Malignant Solid Neoplasms
    Interventions
    Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD); Olaparib (300 mg BID); Durvalumab + Tremelimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-03
    Completion
    2028-10
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Neoplasms
    InterventionNilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD) +3 more
    PhasePhase 2
    Registry statusRecruiting

  • A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

    NCT02451696 · start 2014-01

    Registered record
    Registry ID
    NCT02451696
    Conditions
    Epilepsy; Tuberous Sclerosis Complex; Focal Cortical Dysplasia
    Interventions
    Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-01
    Completion
    2017-12-28
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy; Tuberous Sclerosis Complex; Focal Cortical Dysplasia
    InterventionEverolimus
    PhasePhase 2
    Registry statusCompleted

  • A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.

    NCT02040584 · start 2013-12-20

    Registered record
    Registry ID
    NCT02040584
    Conditions
    Liver Transplant
    Interventions
    Minimisation of TAC; TAC + MMF + corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-20
    Completion
    2016-02-10
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant
    InterventionMinimisation of TAC; TAC + MMF + corticosteroids
    PhasePhase 3
    Registry statusCompleted

  • Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

    NCT02015728 · start 2013-12

    Registered record
    Registry ID
    NCT02015728
    Conditions
    Recurrent Childhood Brain Tumor
    Interventions
    Tumor biology testing; Temozolomide; Etoposide; Sorafenib; Everolimus; Erlotinib; Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-12
    Completion
    2017-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Childhood Brain Tumor
    InterventionTumor biology testing; Temozolomide; Etoposide; Sorafenib +3 more
    PhaseNot applicable
    Registry statusUnknown